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Background. In the catheter laboratory there is a need for
functional tests validating the hemodynamic significance of coro-
nary artery stenosis.
Objectives. It was the objective of our study to compare the
long-term cardiac event rate and the clinical symptoms in patients
with reduced coronary flow velocity reserve (CFVR) and standard
PTCA with patients with normal CFVR and deferred angioplasty.
Methods. Our study included 70 patients with intermediate
coronary artery stenoses (13 f, 57 m; diameter stenosis >50%,
<90%) and an indication for PTCA due to stable angina pectoris
and/or signs of ischemia in noninvasive stress tests. CFVR was
measured distal to the lesion after intracoronary administration
of adenosine using 0.014 inch Doppler-tipped guide wires.
Results. In 22 patients (31%), PTCA was deferred due to a
CFVR >2 2.0 (non-PTCA group). In the remaining 48 patients
(69%) mean CFVR of 1.4 6 0.23 (p < 0.001) was measured (PTCA
group). CFVR increased to 2.0 6 0.51 after angioplasty. During
follow-up (average 15 6 6.0 months), the following major adverse
cardiac events (MACE) occurred: in the PTCA group re-PTCA
was performed in nine patients (18.8%) because of unstable
angina, five patients (10.4%) suffered an acute myocardial infarc-
tion (MI) (two infarctions occurred during the angioplasty, three
patients suffered an infarction during follow-up), two patients
(4.2%) needed blood transfusions due to severe bleedings, two
patients (4.2%) underwent bypass surgery and one patient (2.1%)
died. In the non-PTCA group, angioplasty was necessary only in
two cases (9.1%) during follow-up. We did not observe any MI in
the non-PTCA group.
The overall rate of MACE was significantly lower in the
non-PTCA group compared to the PTCA group (9.1% vs. 33.3%,
p < 0.01). However, only 40% of the patients of the non-PTCA
group were free of angina pectoris at stress. In the PTCA group,
63% did not complain of any symptoms at follow-up (p < 0.05).
Conclusions. We conclude that determination of the CFVR is a
valuable parameter for stratifying the hemodynamic significance
of coronary artery stenosis. PTCA can safely be deferred in
patients with significant coronary stenosis but a CFVR >2 2.0. The
total rate of MACE at follow-up was below 10% among these
patients. However, if PTCA was deferred the number of patients
who are free of angina is lower compared to those patients who
underwent angioplasty.
(J Am Coll Cardiol 1999;33:82–7)
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After two decades of percutaneous coronary angioplasty
(PTCA), the major aim of investigation focuses more and
more on the benefit of angioplasty in coronary artery disease
(CAD) as compared with coronary artery bypass graft surgery
(CABG) and conservative treatment. Due to increasing num-
bers of angioplasty procedures, the relation between risk and
effectiveness is of special interest. Several studies have com-
pared PTCA to medical therapy (1–4). Besides the risk of
adverse outcomes compared with the benefits of PTCA, these
trials have focused on the costs of an angioplasty. On one hand
PTCA offers an earlier and more satisfactory relief of angina
than medical therapy in single-vessel disease. It is associated
with better performance on exercise tests. On the other hand
PTCA initially costs more than medical treatment and is
associated with a higher frequency of complications (3). In
double-vessel disease, the beneficial effects of PTCA compared
to medical therapy may be diminished (4). The ACIP investi-
gators showed an improved prognosis after initial revasculari-
sation compared with angina-guided medical therapy (1). This
was the first prospective, randomized trial showing an improve-
ment of prognosis by PTCA compared to medical therapy.
However, due to limited resources and the risk of adverse
outcomes after PTCA, it is not justified to perform an angio-
plasty in all patients showing angiographically significant cor-
onary stenosis or having signs of ischemia in noninvasive stress
tests.
Angiography alone is an imperfect method for determining
the physiologic relevance of coronary lumen narrowing (5). In
addition, noninvasive stress tests have an imperfect specifica-
tion (6). In the interest of optimization of coronary artery
disease therapy, there is a need for more physiological tests to
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define prospectively the group of patients whose coronary
vessel flow capacity is sufficient despite a stenosis, and there-
fore PTCA seems unnecessary. Measurements of translesional
pressure-flow velocity measurements and of the fractional flow
reserve (FFR) have already been established by clinical studies
(5,7). The registration of coronary flow velocity reserve
(CFVR) can easily be performed. Recent studies have dem-
onstrated a correlation between CFVR after angioplasty and
the clinical outcome (8). However, the value of the CFVR to
evaluate the indication for PTCA has not been proven so far in
a prospective study. Therefore, we tested the hypothesis that
CFVR is able to distinguish those patients who may benefit
from an angioplasty procedure from those for whom PTCA
seems unnecessary.
Methods
Patient selection. Between July 1994 and December 1996,
2,760 PTCAs were performed in our clinic. In this prospective
trial we consecutively included 70 patients who were referred
for elective angioplasty during certain terms of this period. All
patients met the inclusion criteria as shown in Table 1. They
were referred for coronary angioplasty due to a de novo lesion
of .50%. In addition, they reported chest pain at stress and/or
they showed signs of ischemia in noninvasive stress tests.
Precatheterization stress tests were performed by bicycle exer-
cise testing or thallium scintigraphy in a standard manner
without antianginal drugs. All patients had to reach at least
85% of their maximum heart rate during exercise. Bicycle
stress test was considered positive if ST-segment depression of
$0.2 mV in two standard leads was measured. Scintigraphy
was considered positive if thallium storage was reversibly
diminished in at least two regions in the area of interest.
Patients were excluded if more than one lesion had to be
treated, collateral flow was present, the left main was stenosed,
the patient had unstable angina or angina at rest. Further
exclusion criteria were previous myocardial infarction or re-
duced coronary blood flow (,TIMI III) in the vessel of
interest.
All patients had given written informed consent to take part
in the study. They were well informed about the aim and the
strategy of treatment evaluated in the study.
Study protocol. Coronary angiography was performed in
standard manner by femoral approach with 7F Judkins guiding
catheter. After intracoronary injection of 0.2 mg of nitroglyc-
erin, quantitative coronary angiography (QCA) of the target
lesion was obtained. QCA was performed by Philips DCI
automated coronary analysis using the 7F guiding catheter as
reference standard (9). The lesion severity was determined by
percent diameter stenosis relative to angiographically normal
diameter.
A 0.0140 Doppler guide wire (FlowWire™, Cardiometrics,
Mountain View, California) was placed 1–2 cm distal to the
stenosis after intravenous administration of 10,000 IU of
heparin. The 175 cm long wire has an integrated piezoelectric
ultrasound transducer in the tip. The signal of the 12 MHz
pulsed Doppler was analyzed by a computer system (Flow-
Map™, Cardiometrics, Mountain View, California) using fast
Fourier transformation. The validity of these Doppler wire
measurements has been demonstrated in various settings
(10,11). The mechanical and electrical characteristics of this
Doppler guide wire are reported in detail elsewhere (12). The
average peak velocity (APV) 4 mm distal of the tip of the
Doppler wire was obtained from the spectral signals averaged
over two cardiac cycles. After registration of APV at rest,
adenosine was injected through the guiding catheter to induce
coronary hyperemia. We used 12 mg for the right and 18 mg for
the left coronary artery. The coronary flow velocity reserve
(CFVR) was computed as the ratio of hyperemic to basal APV.
In those patients who had CFVR $2, PTCA was deferred and
they were allotted to the non-PTCA group. In the remaining
patients with CFVR ,2, balloon angioplasty was performed in
standard manner (PTCA group) after administration of an
additional 5,000 IU of heparin. Balloon inflation or stent
implantation was performed until an angiographically satisfy-
ing result was achieved in all patients of the PTCA group
(degree of stenosis ,30%).
In addition, all 70 patients received optimal medication
consisting of aspirin, nitrates, beta-adrenergic blocking agents,
ACE-inhibitors and lipid lowering drugs as appropriate to each
individual. Patients with stents received ticlopidine 250 mg bid
for four weeks.
Abbreviations and Acronyms
APV 5 average peak velocity
CABG 5 coronary artery bypass graft surgery
CAD 5 coronary artery disease
CCS 5 Canadian Cardiological Society
CFVR 5 coronary flow velocity reserve
FFR 5 fractional flow reserve
MACE 5 major adverse cardiac event
MI 5 myocardial infarction
NYHA 5 New York Heart Association
PTCA 5 percutaneous transluminal coronary angioplasty
QCA 5 quantitative coronary angiography
RFVR 5 relative coronary flow velocity reserve
SPECT 5 single-photon emission computed tomography
Table 1. Inclusion and Exclusion Criteria
Inclusion Criteria Exclusion Criteria
z Written informed consent z Acute myocardial infarction or
z Age $18 years unstable angina
z Positive stress test and/or stable z Stenosis of the left main
Angina during exercise z CCS class IV
z De novo lesion z NYHA class IV
z Only one lesion to be treated z Pregnancy (in women)
z Degree of stenosis .50% & ,90% z Previous Q-wave infarction/hypokinesia
z TIMI flow III in the region of interest
z Vessel suitable for angioplasty z Known malignancy which would
interfere follow-up
z Relevant collateral flow
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Clinical follow-up. We defined as major adverse cardiac
event (MACE) the occurrence of severe bleeding requiring
blood transfusion, repeated PTCA or primary PTCA in the
non-PTCA group, acute myocardial infarction, coronary by-
pass surgery, cardiac death during angioplasty or during
follow-up period. A myocardial infarction was considered if an
increase of creatine kinase to more than twice the normal value
was measured and a Q-wave developed in at least two leads of
standard ECG recordings. Severe bleeding was defined as
blood loss requiring transfusion of blood or surgical interven-
tion. Follow-up period was at least six months. All patients
underwent physical examination and noninvasive stress tests
(bicycle exercise testing or thallium scintigraphy) in our clinic.
The same stress test protocol was used at follow-up examina-
tion as at the beginning of the study. All patients had to cycle
until at least $85% of their maximum heart rate was reached.
In those patients who reported new onset or aggravation of
angina or showed pathological results in noninvasive stress test
at follow-up, reangiography was performed.
Statistical analysis. Data are reported for 70 patients.
They were divided into two groups after measurement of
coronary flow velocity reserve. All values are expressed as
mean 6 SD and the percentage in each group. P values were
calculated using paired Student t tests for statistical analysis of
continuous variables within a group. Associations between the
two groups were tested for, using two-tailed unpaired Student
t tests for continuous data after F-test determination of
standard distribution or chi-square (x2) test without continuity
adjustment for categorical data. A p value ,0.05 was consid-
ered statistically significant.
Results
The clinical data of the 70 patients are shown in Table 2.
Angiographic characteristics are summarized in Table 3. Age,
gender, NYHA class, CCS class, extent of coronary artery
disease, results of stress tests and incidence of angina pectoris
were comparable between the two groups at the time of
inclusion (Fig. 1).
The degree of coronary artery stenosis was significantly
lower in those patients who had a CFR $2.0 compared with
the PTCA group (66.1% 6 8.52 vs. 76.5% 6 8.35%, p , 0.05).
However, for all patients the indication for PTCA was made by
independent cardiologists.
Acute results. In 22 patients angioplasty was deferred due
to a CFVR $2.0 (non-PTCA group). No acute complication
was observed among this group. New York Heart Association
(NYHA) and angina pectoris status have been improved by
optimization of medical therapy.
In the PTCA group, the CFVR increased from 1.4 to 2.0
after angiographically successful angioplasty (p , 0.001). The
degree of stenosis was reduced from 76.5% to 16.5% (p ,
0.001). NYHA class was also improved in the PTCA group.
The incidence of angina pectoris was reduced nearly one class
according to CCS (Canadian Cardiac Society). Among those
who underwent PTCA, two patients (4.2%) suffered an acute
myocardial infarction. Another patient (2.1%) underwent
emergency coronary bypass surgery after dissection into the
left main. In two patients (4.2%) bleeding occurred at the
femoral puncture site requiring blood transfusion; surgical
intervention was necessary in one of these cases. In total, we
noticed major adverse cardiac events (MACE) related to the
initial PTCA in five patients in the PTCA group (10.4%).
Follow-up results. The follow-up period was 15 6 6.0
months (range: 6 to 30 months). At follow-up, there was no
difference in medical treatment between the PTCA and the
non-PTCA group (data not presented). In the non-PTCA
group, we found progression of CAD with an aggravation of
angina in two patients (9.1%). In these two patients, PTCA was
Table 2. Clinical Data of 70 Patients
Non-PTCA group
CFVR $2 (n 5 22)
PTCA Group
CFVR ,2 (n 5 48)
Age (years) 58 6 7.6 59 6 12.2 n.s.
Sex (female/male) 6 f/16 m (27.3%) 7 f/41 m (14.6%) n.s.
Previous Q-wave infarction (not supplied
by the vessel of interest)
2 (9%) 3 (6%) n.s.
Follow-up (months) 15.0 6 5.66 15.1 6 6.13 n.s.







at discharge 1.8 6 0.37 — 1.9 6 0.43 — n.s.
at follow-up 2.0 6 0.60 1.9 6 0.67 n.s.







at discharge 1.7 6 0.47 — 1.5 6 0.51 — n.s.
at follow-up 2.1 6 0.76 1.9 6 0.89 n.s.





at follow-up 8 (36.4%) 18 (37.5%) n.s.





at follow-up 13 (59.1%) 18 (37.5%) *
Mean value 6 standard deviation; CFVR 5 coronary flow velocity reserve; NYHA 5 New York Heart Association;
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performed after 11 and 12 months, respectively, both in an
outside institutions while measuring the CFVR.
Among those with an initially normal CFVR in the target
vessel, three other patients (13.6%) underwent angiography
during follow-up. They showed abnormalities during stress
ECG in different leads as before angiography. However, they
did not require PTCA. The degree of coronary diameter
narrowing remained unchanged in those five patients of the
non-PTCA group who were restudied by coronary angiogra-
phy. Neither an acute myocardial infarction nor cardiac death
was observed in this group. Thirteen patients of the non-PTCA
group (59.1%) reported chest pain at follow-up examination.
Eight patients (36.4%), including those two who were dilated,
showed signs of ischemia in noninvasive stress tests. Consider-
ing PTCA, MACE occurred in two patients of the non-PTCA
group (9.1%) during follow-up.
In the PTCA group, three patients (6.3%) suffered myocar-
dial infarction during follow-up. Two of them underwent
re-PTCA, one patient had emergency coronary bypass surgery
two years after initial angioplasty due to occlusion. Other than
the two emergency PTCAs, an additional seven patients
(14.6%) underwent re-PTCA for relevant restenosis. Another
15 patients (31.25%) underwent angiography during follow-up
because of new onset or aggravation of angina or suspect
results in noninvasive stress tests. They did not require rein-
tervention. Eighteen patients (37.5%), including the seven
patients who had re-PTCA, reported angina at stress at
follow-up. Eight of them, plus 10 other patients who were free
of angina showed signs of ischemia in noninvasive stress tests
among the PTCA group (37.5%).
One patient (2.1%) died of ventricular fibrillation four
months after initial angioplasty. Since autopsy was denied, it
was unclear whether he had an acute myocardial infarction in
the vessel of interest. In summary, 11 patients of the PTCA
group (22.9%) had MACE during the follow-up period. The
total MACE rate in the PTCA group at follow-up was approx-
imately 30%.
Discussion
In this prospective study, we tested the method of deferring
PTCA in patients with significant coronary stenosis yet suffi-
cient CFVR. Deferring angioplasty was safe and had a favor-
able outcome in 22 patients with CFVR $2. The rate of
MACE was significantly elevated in those patients who had
CFVR ,2 and underwent PTCA compared to the patients
with normal CFVR and deferred angioplasty (Fig. 2). Despite
Table 3. Angiographic Characteristics and Follow-up Results of 70 Patients
Non-PTCA Group
CFVR $2 (n 5 22)
PTCA Group
CFVR ,2 (n 5 48)
Vessel of interest Left anterior descending 13 (59.1%) 23 (47.9%) n.s.
Circumflex 3 (13.6%) 14 (29.2%) n.s.
Right coronary artery 6 (27.3%) 11 (22.9%) n.s.
Degree of stenosis pre PTCA 66.1 6 8.52% 76.5 6 8.35% *
post PTCA 16.5 6 20.5%
At follow-up 65.0 6 18.03% (5 pts) 49.2 6 31.41% (25pts) n.s.
CAD (number of vessels) 1.8 6 0.73 1.9 6 0.76 n.s.
CFVR pre PTCA 2.7 6 0.75 1.4 6 0.23 ***
post PTCA 2.0 6 0.51
Myocardial infarction:
acute 0 2 (4.2%)
follow-up 0 3 (6.3%)
Other complications:
severe bleeding 0 2 (4.2%)
coronary bypass surgery 0 2 (4.2%)
(Re-) PTCA 2 (9.1%) 9 (18.8%) n.s.
sudden cardiac death 0 1 (2.1%)
3 MACE Acute 0 5 (10.4%)
Follow-up 2 (9.1%) 11 (22.9%) n.s.
¥ 2 (9.1%) 16 (33.3%) **
CAD 5 coronary artery disease; CFVR 5 coronary flow velocity reserve; MACE 5 major adverse cardiac event;
t test or x2-test: n.s. 5 not significant; * 5 p , 0.05; ** 5 p , 0.01; *** 5 p , 0.001.
]***
]***
Figure 1. Severity of angina pectoris (according to Canadian Cardiac
Society) of patients who reported angina at stress before angioplasty,
at discharge and after follow-up of 15 months. (n.s.: t test not
significant).
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angina pectoris at stress, we did not observe any disadvantage
in the non-PTCA group after deferred angioplasty compared
to the PTCA group.
Further trials should prove and establish this method for
adaptation in the daily catheter laboratory routine. Due to the
relatively small cohort, we are not able to show any difference
between single and multivessel disease. Multicenter trials with
greater numbers of patients could be a valid basis for replacing
other functional tests with CFVR-detection. In our study
measurements of CFVR identified those patients in whom it
was safe to defer angioplasty.
Other functional tests. Noninvasive tests for detecting
myocardial ischemia are associated with a great number of
false positive or negative results (6,13). There are several
factors influencing the predictive value of noninvasive stress
tests or reported angina pectoris at stress (14–16). Even
invasive examination by quantitative coronary angiography
remains an imperfect method to determine the impact of
coronary artery stenosis (17,18). Measurements of transle-
sional pressure gradient can also be used for analyzing the
hemodynamic significance of coronary artery stenosis (19). In
combination with analysis of flow velocity proximal to distal of
the stenosis, it is a valid parameter for clinical decision making
(5). Kern et al. showed the feasibility and safety of deferring
angioplasty in patients with normal translesional pressure-flow
velocity measurements in a study design similar to the one used
in our investigation. The average CFVR in the patients with
coronary artery stenosis of intermediate severity in whom
PTCA was deferred due to the translesional pressure-flow
velocity measurements was 2.0 6 0.64. Although nearly half of
their patients had CFVR below two, they did not observe any
adverse outcome in patients with deferred PTCA.
Ideal coronary flow velocity reserve. We took the cutoff
value of 2.0 for “normal” CFVR due to findings in single-
photon emission computed tomography (SPECT) (20,21).
Although SPECT is an imperfect method for determination of
the hemodynamic significance of coronary artery stenosis, 2.0
is a clear-cut value for decision making in daily clinical
practice. The FACTS Study Group found a cut point for
optimal sensitivity and specificity of CFVR at 1.7 in compari-
son with SPECT and Doppler flow velocity measurements in
patients with moderate CAD (22). The DEBATE Study
showed a cutoff of 2.5 for CFVR immediately after PTCA to
predict the incidence of MACE in a retrospective analysis (8).
Thus, optimization of PTCA results according to a
CFVR $ 2.5 might reduce the rate of MACE during follow-up,
but this was not the aim of our study. However, the DEBATE
Study also indicates that decision making by angiographic
criteria is insufficient.
Safety and cost. Our data demonstrate the safety, feasibil-
ity and clinical outcome of deferring angioplasty of coronary
artery stenosis associated with “normal” CFVR. The risk of an
adverse outcome was significantly lower among the 22 cases in
whom PTCA was deferred due to normal CFVR compared
with the patients who underwent angioplasty. The costs of
Doppler guide wire compared with the resources which can be
saved by deferring angioplasty in 30% of patients are much
lower especially if the higher incidence of re-PTCA are taken
into account.
Methodical limitations. The patients with single vessel
disease medical therapy showed better long term outcome, but
in multivessel disease PTCA seems to be more favorable (4).
We did not distinguish patients with single vessel disease from
those with significant lumen narrowing in two or three vessels.
It should be one aspect of bigger trials to test which patients
will benefit from deferred PTCA on the basis of CFVR-
detection.
Collateral flow can provide sufficient supply in the distal
myocardium even if the CFVR is reduced. Since visible
collateral flow in the vessel of interest was an exclusion criteria,
the collateral flow was of minor importance for the flow
velocity measurements in this study. Measurements of the
(FFR) by intracoronary pressure wire may be superior in accurate
determination of functional severity of coronary artery stenoses in
vessels with relevant collateral flow (7,23–25).
Since reangiography was not performed in all patients, we
are not able to quantify the degree of progression of CAD. On
one hand there might be some nonsymptomatic restenosis in
the patients who underwent PTCA, but on the other hand the
CFVR may have decreased in some patients with deferred
PTCA. Due to the unobtrusive clinical outcome, we failed to
perform reangiography in these patients.
Recently it was suggested to take the relative CFVR
(RFVR) to reduce the interindividual variations of CFVR
(26). The RFVR is defined as the ratio of absolute CFVR of
the diseased vessel divided by CFVR measured in an angio-
graphically normal reference vessel (27). The RFVR might be
able to consider microvascular disease better than CFVR
without flow velocity measurements in a reference vessel.
Clinical relevance. The rate of immediate PTCA during
primarily diagnostic procedure is growing (28). Measurements
of CFVR offer the opportunity to validate the indication for
PTCA if noninvasive stress tests are missing and angina
pectoris is untypical. Beyond this application there is some-
times a need to distinguish the relevant stenosis from those
which do not require angioplasty in multivessel disease. A
major number of patients in the catheter laboratory can benefit
Figure 2. The slopes reflect the relation between risk of major adverse
cardiac event (MACE: severe bleeding, re-PTCA, acute myocardial
infarction, coronary bypass surgery, sudden cardiac death) and benefit
(number of patients who are free of angina pectoris) in the PTCA
subgroup (n 5 48) and the non-PTCA subgroup (n 5 22).
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from functional testing of stenosis severity before elective
PTCA. Measurements of CFVR can also be used to improve
the result of PTCA beyond angiography (29). Physiologically
guided angioplasty can help to reduce the incidence of major
adverse cardiac events and the costs.
Conclusion. We conclude that determination of the CFVR
is a valuable parameter for stratifying the hemodynamic sig-
nificance of coronary artery stenosis. A “normal” CFVR can be
found in about 30% of patients with angiographically signifi-
cant stenoses who show an indication for PTCA due to stable
angina pectoris or positive noninvasive stress test. PTCA can
safely be deferred in patients with significant coronary stenosis
but CFVR $ 2.0.
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